Human regulatory T cells suppress proliferation of B lymphoma cells

Leukemia and Lymphoma

Volumn 57, Issue 8, 2016, Pages 1903-1920

  Grygorowicz, Monika Anna ^a   Biernacka, Marzena ^a   Bujko, Mateusz ^a   Nowak, Eliza ^a   Rymkiewicz, Grzegorz ^a   Paszkiewicz Kozik, Ewa ^a   Borycka, Ilona Sara ^a   Bystydzienski, Zbigniew ^a   Walewski, Jan ^a   Markowicz, Sergiusz ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

B cell lymphoma; dendritic cells; immune regulation; regulatory T cells; tumor immunology

Indexed keywords

5' NUCLEOTIDASE; BIOLOGICAL MARKER; CD39 ANTIGEN; CD40 LIGAND; CHEMOKINE RECEPTOR CXCR5; DNA; GAMMA INTERFERON; GRANZYME A; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; L SELECTIN; RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; FORKHEAD TRANSCRIPTION FACTOR; IL2 PROTEIN, HUMAN; INTERLEUKIN 2;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; B-CELL LYMPHOMA CELL LINE; CANCER CELL CULTURE; CD4+ CD25+ CD127LO T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CELL EXPANSION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; DNA METHYLATION; FEMALE; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; LYMPHOMA CELL; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; PHENOTYPE; PLASMABLASTIC LYMPHOMA; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; B LYMPHOCYTE; DRUG EFFECTS; FINE NEEDLE ASPIRATION BIOPSY; FLOW CYTOMETRY; IMMUNOLOGY; LYMPH NODE; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PRIMARY CELL CULTURE; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; B-LYMPHOCYTES; BIOPSY, FINE-NEEDLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE TECHNIQUES; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-2; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPH NODES; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PRIMARY CELL CULTURE; SIROLIMUS; T-LYMPHOCYTES, REGULATORY;

EID: 84954209804     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1121260     Document Type: Article

References (98)

1. S.Sakaguchi, M.Miyara, C.M.Costantino, et al. FOXP3 + regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10:490–500.
2. T.J.Curiel Tregs and rethinking cancer immunotherapy. J Clin Invest. 2007;117:1167–1174.
3. J.Carreras, A.Lopez-Guillermo, B.C.Fox,. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood. 2006;108:2957–2964.
4. A.Tzankov, C.Meier, P.Hirschmann,. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica. 2008;93:193–200.
5. D.de Jong, A.Koster, A.Hagenbeek,. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica. 2009;94:70–77.
6. B.E.Wahlin, M.Aggarwal, S.Montes-Moreno,. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1-positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res. 2010;16:637–650.
7. N.R.Lee, E.K.Song, K.Y.Jang,. Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma. 2008;49:247–256.
8. T.Alvaro, M.Lejeune, M.T.Salvado,. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res. 2005;11:1467–1473.
9. T.W.Kelley, B.Pohlman, P.Elson, et al. The ratio of FOXP3 + regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol. 2007;128:958–965.
10. A.M.Glas, L.Knoops, L.Delahaye,. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol. 2007;25:390–398.
11. S.Schreck, D.Friebel, M.Buettner,. Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol. 2009;27:31–39.
12. P.Farinha, A.Al-Tourah, K.Gill,. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood. 2010;115:289–295.
13. Z.Z.Yang, A.J.Novak, M.J.Stenson,. Intratumoral CD4 + CD25 + regulatory T-cell-mediated suppression of infiltrating CD4 + T cells in B-cell non-Hodgkin lymphoma. Blood. 2006;107:3639–3646.
14. M.Glowala-Kosinska, A.Chwieduk, J.Nieckula,. Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B-cell lymphoma. Eur J Haematol. 2013;91:122–128.
15. K.Giannopoulos, M.Schmitt, M.Kowal,. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep. 2008;20:677–682.
16. T.Alvaro, M.Lejeune, P.Escriva,. Appraisal of immune response in lymphoproliferative syndromes: a systematic review. Crit Rev Oncol Hematol. 2009;70:103–113.
17. H.W.Lim, P.Hillsamer, C.H.Kim Regulatory T cells can migrate to follicles upon T cell activation and suppress GC-Th cells and GC-Th cell-driven B cell responses. J Clin Invest. 2004;114:1640–1649.
18. H.W.Lim, P.Hillsamer, A.H.Banham, et al. Cutting edge: direct suppression of B cells by CD4 + CD25 + regulatory T cells. J Immunol. 2005;175:4180–4183.
19. D.M.Zhao, A.M.Thornton, R.J.Di Paolo, et al. Activated CD4 + CD25 + T cells selectively kill B lymphocytes. Blood. 2006;107:3925–3932.
20. C.A.Lindqvist, L.H.Christiansson, I.Thorn,. Both CD4 + FoxP3 + and CD4 + FoxP3- T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro. Immunology. 2011;133:296–306.
21. P.A.Taylor, C.J.Lees, B.R.Blazar The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99:3493–3499.
22. P.Trzonkowski, M.Bieniaszewska, J.Juscinska,. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4 + CD25 + CD127- T regulatory cells. Clin Immunol. 2009;133:22–26.
23. M.DiIanni, F.Falzetti, A.Carotti,. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011;117:3921–3928.
24. C.G.Brunstein, J.S.Miller, Q.Cao,. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011;117:1061–1070.
25. A.M.Thornton, E.M.Shevach Suppressor effector function of CD4 + CD25 + immunoregulatory T cells is antigen nonspecific. J Immunol. 2000;164:183–190.
26. M.Battaglia, A.Stabilini, M.G.Roncarolo Rapamycin selectively expands CD4+ CD25+ FoxP3+ regulatory T cells. Blood. 2005;105:4743–4748.
27. G.Wieczorek, A.Asemissen, F.Model,. Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res. 2009;69:599–608.
28. W.Liu, A.L.Putnam, Z.Xu-Yu,. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006;203:1701–1711.
29. N.Seddiki, B.Santner-Nanan, J.Martinson,. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med. 2006;203:1693–1700.
30. M.Miyara, Y.Yoshioka, A.Kitoh,. Functional delineation and differentiation dynamics of human CD4 + T cells expressing the FoxP3 transcription factor. Immunity. 2009;30:899–911.
31. W.J.Grossman, J.W.Verbsky, W.Barchet,. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity. 2004;21:589–601.
32. W.J.Grossman, J.W.Verbsky, B.L.Tollefsen,. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood. 2004;104:2840–2848.
33. R.Woroniecka, G.Rymkiewicz, B.Grygalewicz,. Cytogenetic and flow cytometry evaluation of Richter syndrome reveals MYC, CDKN2A, IGH alterations with loss of CD52, CD62L and increase of CD71 antigen expression as the most frequent recurrent abnormalities. Am J Clin Pathol. 2015;143:25–35.
34. N.S.Andersen, J.K.Larsen, J.Christiansen,. Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures. Blood. 2000;96:2219–2225.
35. S.S.Neelapu, S.Baskar, B.L.Gause,. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. Clin Cancer Res. 2004;10:8309–8317.
36. M.Travert, P.Ame-Thomas, C.Pangault,. CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-kappaB activation and up-regulation of c-FLIP and Bcl-xL. J Immunol. 2008;181:1001–1011.
37. D.Ito, A.M.Frantz, C.Williams,. CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: a tool for in vitro preclinical studies with primary B-cell malignancies. Leuk Lymphoma. 2012;53:1390–1398.
38. S.Haxhinasto, D.Mathis, C.Benoist The AKT-mTOR axis regulates de novo differentiation of CD4+ Foxp3+ cells. J Exp Med. 2008;205:565–574.
39. S.Sauer, L.Bruno, A.Hertweck,. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci USA. 2008;105:7797–7802.
40. P.Hoffmann, T.J.Boeld, R.Eder,. Loss of FOXP3 expression in natural human CD4 + CD25 + regulatory T cells upon repetitive in vitro stimulation. Eur J Immunol. 2009;39:1088–1097.
41. L.Gabrysova, J.R.Christensen, X.Wu,. Integrated T-cell receptor and costimulatory signals determine TGF-beta-dependent differentiation and maintenance of Foxp3 + regulatory T cells. Eur J Immunol. 2011;41:1242–1248.
42. N.Marek, M.Bieniaszewska, A.Krzystyniak,. The time is crucial for ex vivo expansion of T regulatory cells for therapy. Cell Transplant. 2011;20:1747–1758.
43. E.Tresoldi, I.Dell'Albani, A.Stabilini,. Stability of human rapamycin-expanded CD4 + CD25 + T regulatory cells. Haematologica. 2011;96:1357–1365.
44. D.Valmori, V.Tosello, N.E.Souleimanian,. Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4 + T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4 + T cells. J Immunol. 2006;177:944–949.
45. H.J.Shin, J.Baker, D.B.Leveson-Gower,. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4 + CD25 + Foxp3 + regulatory T cells. Blood. 2011;118:2342–2350.
46. A.Toker, D.Engelbert, G.Garg,. Active demethylation of the Foxp3 locus leads to the generation of stable regulatory T cells within the thymus. J Immunol. 2013;190:3180–3188.
47. Y.Zheng, S.Josefowicz, A.Chaudhry,. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature. 2010;463:808–812.
48. J.K.Polansky, L.Schreiber, C.Thelemann,. Methylation matters: binding of Ets-1 to the demethylated Foxp3 gene contributes to the stabilization of Foxp3 expression in regulatory T cells. J Mol Med (Berl). 2010;88:1029–1040.
49. Y.Feng, A.Arvey, T.Chinen,. Control of the inheritance of regulatory T cell identity by a cis element in the Foxp3 locus. Cell. 2014;158:749–763.
50. L.Hansmann, C.Schmidl, J.Kett,. Dominant Th2 differentiation of human regulatory T cells upon loss of FOXP3 expression. J Immunol. 2012;188:1275–1282.
51. C.Schmidl, L.Hansmann, R.Andreesen,. Epigenetic reprogramming of the RORC locus during in vitro expansion is a distinctive feature of human memory but not naïve Treg. Eur J Immunol. 2011;41:1491–1498.
52. X.Zhou, S.L.Bailey-Bucktrout, L.T.Jeker,. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol. 2009;10:1000–1007.
53. M.Ayyoub, F.Deknuydt, I.Raimbaud,. Human memory FOXP3 + Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma.t. Proc Natl Acad Sci USA. 2009;106:8635–8640.
54. D.Valmori, C.Raffin, I.Raimbaud, et al. **Human RORγt + TH17 cells preferentially differentiate from naive FOXP3 + Treg in the presence of lineage-specific polarizing factors. Proc Natl Acad Sci USA. 2010;107:19402–19407.
55. G.Beriou, C.M.Costantino, C.W.Ashley,. IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood. 2009;113:4240–4249.
56. Y.P.Rubtsov, R.E.Niec, S.Josefowicz,. Stability of the regulatory T cell lineage in vivo. Science. 2010;329:1667–1671.
57. Y.Gao, F.Lin, J.Su,. Molecular mechanisms underlying the regulation and functional plasticity of FOXP3(+) regulatory T cells. Genes Immun. 2012;13:1–13.
58. S.Sakaguchi, D.A.Vignali, A.Y.Rudensky,. The plasticity and stability of regulatory T cells. Nat Rev Immunol. 2013;13:461–467.
59. W.Fu, A.Ergun, T.Lu,. A multiply redundant genetic switch 'locks in' the transcriptional signature of regulatory T cells. Nat Immunol. 2012;13:972–980.
60. A.Chaudhry, D.Rudra, P.Treuting,. CD4 + regulatory T cells control TH17 responses in a Stat3-dependent manner. Science. 2009;326:986–991.
61. Y.Zheng, A.Chaudhry, A.Kas,. Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature. 2009;458:351–356.
62. M.A.Koch, G.Tucker-Heard, N.R.Perdue,. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol. 2009;10:595–602.
63. Y.Wang, A.Souabni, R.A.Flavell, et al. An intrinsic mechanism predisposes Foxp3-expressing regulatory T cells to Th2 conversion in vivo. J Immunol. 2010;185:5983–5992.
64. Y.Wang, M.A.Su, Y.Y.Wan An essential role of the transcription factor GATA-3 for the function of regulatory T cells. Immunity. 2011;35:337–348.
65. F.Yu, S.Sharma, J.Edwards,. Dynamic expression of transcription factors T-bet and GATA-3 by regulatory T cells maintains immunotolerance. Nat Immunol. 2015;16:197–206.
66. S.Dong, S.Maiella, A.Xhaard,. Multiparameter single-cell profiling of human CD4 + FOXP3 + regulatory T-cell populations in homeostatic conditions and during graft-versus-host disease. Blood. 2013;122:1802–1812.
67. E.d'Hennezel, E.Yurchenko, E.Sgouroudis,. Single-cell analysis of the human T regulatory population uncovers functional heterogeneity and instability within FOXP3 + cells. J Immunol. 2011;186:6788–6797.
68. T.Ito, S.Hanabuchi, Y.H.Wang,. Two functional subsets of FOXP3 + regulatory T cells in human thymus and periphery. Immunity. 2008;28:870–880.
69. H.Husson, A.S.Freedman, A.A.Cardoso,. CXCL13 (BCA-1) is produced by follicular lymphoma cells: role in the accumulation of malignant B cells. Br J Haematol. 2002;119:492–495.
70. K.C.Chang, X.Huang, L.J.Medeiros, et al. Germinal centre-like versus undifferentiated stromal immunophenotypes in follicular lymphoma. J Pathol. 2003;201:404–412.
71. L.Machado, R.Jarrett, S.Morgan,. Expression and function of T cell homing molecules in Hodgkin's lymphoma. Cancer Immunol Immunother. 2009;58:85–94.
72. A.van den Berg, L.Visser, S.Poppema High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. Am J Pathol. 1999;154:1685–1691.
73. J.Teruya-Feldstein, E.S.Jaffe, P.R.Burd,. Differential chemokine expression in tissues involved by Hodgkin's disease: direct correlation of eotaxin expression and tissue eosinophilia. Blood. 1999;93:2463–2470.
74. M.Fischer, M.Juremalm, N.Olsson,. Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int J Cancer. 2003;107:197–201.
75. C.Buri, M.Korner, P.Scharli,. CC chemokines and the receptors CCR3 and CCR5 are differentially expressed in the nonneoplastic leukocytic infiltrates of Hodgkin disease. Blood. 2001;97:1543–1548.
76. C.V.Hedvat, E.S.Jaffe, J.Qin,. Macrophage-derived chemokine expression in classical Hodgkin's lymphoma: application of tissue microarrays. Mod Pathol. 2001;14:1270–1276.
77. P.Ghia, G.Strola, L.Granziero,. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L + T cells by producing CCL22. Eur J Immunol. 2002;32:1403–1413.
78. A.Burkle, M.Niedermeier, A.Schmitt-Graff,. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood. 2007;110:3316–3325.
79. S.Ek, E.Bjorck, C.M.Hogerkorp,. Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival. Int J Cancer. 2006;118:2092–2097.
80. J.Ermann, P.Hoffmann, M.Edinger,. Only the CD62L + subpopulation of CD4 + CD25 + regulatory T cells protects from lethal acute GVHD. Blood. 2005;105:2220–2226.
81. P.T.Sage, L.M.Francisco, C.V.Carman, et al. The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood. Nat Immunol. 2013;14:152–161.
82. N.Dakappagari, S.N.Ho, R.D.Gascoyne,. CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non-Hodgkin lymphoma. Cytometry B Clin Cytom. 2012;82:112–119.
83. Z.Saze, P.J.Schuler, C.S.Hong,. Adenosine production by human B cells and B cell-mediated suppression of activated T cells. Blood. 2013;122:9–18.
84. T.Kobata, S.Jacquot, S.Kozlowski,. CD27-CD70 interactions regulate B-cell activation by T cells. Proc Natl Acad Sci USA. 1995;92:11249–11253.
85. J.B.Wing, S.Sakaguchi Foxp3(+) T(reg) cells in humoral immunity. Int Immunol. 2014;26:61–69.
86. M.Gupta, J.J.Han, M.Stenson,. Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. Blood. 2012;119:2844–2853.
87. S.Morimoto, Y.Kanno, Y.Tanaka,. CD134L engagement enhances human B cell Ig production: CD154/CD40, CD70/CD27, and CD134/CD134L interactions coordinately regulate T cell-dependent B cell responses. J Immunol. 2000;164:4097–4104.
88. G.Epron, P.Ame-Thomas, J.Le Priol,. Monocytes and T cells cooperate to favor normal and follicular lymphoma B-cell growth: role of IL-15 and CD40L signaling. Leukemia. 2012;26:139–148.
89. A.G.Ramsay, A.J.Johnson, A.M.Lee,. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118:2427–2437.
90. A.G.Ramsay, A.J.Clear, G.Kelly,. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood. 2009;114:4713–4720.
91. A.G.Ramsay, A.J.Clear, R.Fatah, et al. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood. 2012;120:1412–1421.
92. R.Yamamoto, M.Nishikori, T.Kitawaki,. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood. 2008;111:3220–3224.
93. J.H.Myklebust, J.M.Irish, J.Brody,. High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood. 2013;121:1367–1376.
94. D.K.Banerjee, M.V.Dhodapkar, E.Matayeva,. Expansion of FOXP3 high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood. 2006;108:2655–2661.
95. W.Reichardt, C.Durr, D.von Elverfeldt,. Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation. J Immunol. 2008;181:4770–4779.
96. R.Houot, R.Levy Tcell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood. 2009;113:3546–3552.
97. P.Hoffmann, J.Ermann, M.Edinger,. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196:389–399.
98. M.Edinger, P.Hoffmann, J.Ermann,. CD4 + CD25 + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9:1144–1150.